Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04810091 · ClinicalTrials.gov registry record · Phase 3
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
A Phase 3 study of Metastatic Neuroendocrine Neoplasm and Locally Advanced Neuroendocrine Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 79
- Enrollment target
- 1
- Study location
NCT04810091 is a Phase 3 study of Metastatic Neuroendocrine Neoplasm and Locally Advanced Neuroendocrine Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 79 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04810091, a Phase 3 study of Metastatic Neuroendocrine Neoplasm and Locally Advanced Neuroendocrine Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 79 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and carcinoid heart disease.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Placebo Administration
- DRUG Telotristat Ethyl
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2026-08-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04810091
The ClinicalTrials.gov registry entry for NCT04810091 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Neuroendocrine Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT04810091 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04810091 about?
NCT04810091 is a clinical study titled "Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor". This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin ...
What is the current status of trial NCT04810091?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 79 participants. The study started on 2021-05-18. Estimated completion is 2026-08-03.
What conditions does trial NCT04810091 study?
This clinical trial studies the following conditions: Metastatic Neuroendocrine Neoplasm, Locally Advanced Neuroendocrine Neoplasm.
What interventions are being tested in trial NCT04810091?
The interventions under investigation include: Questionnaire Administration (OTHER), Placebo Administration (DRUG), Telotristat Ethyl (DRUG).
Who is sponsoring clinical trial NCT04810091?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04810091 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Neuroendocrine Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Neuroendocrine Neoplasm
All registered trials for this condition
Locally Advanced Neuroendocrine Neoplasm
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.